SlideShare a Scribd company logo
1 of 10
What are the different
epidemiological studies
that can be conducted in
respiratory research
An Academic presentation by
Dr. Nancy Agnes, Head, Technical Operations, Pubrica
Group: www.pubrica.com
Email: sales@pubrica.com
• Chronic obstructive pulmonary disease (COPD) prevalence has been thoroughly investigated,
particularly in Western Europe and North America.
• Few of these data are directly comparable because of survey discrepancies in the mix of research
populations, disease diagnosis standards, and risk factor definitions.
• Few community studies have explored COPD phenotypes and incorporated methods of characterizing
the illness other than spirometry.
In brief
• Chronic obstructive pulmonary disease (COPD) is now the fourth leading cause of mortality globally.
The illness is anticipated to reach third place by 2020.
• COPD prevalence has been thoroughly researched, particularly in Western Europe and North America.
However, few of the data are directly comparable due to changes in the surveys' makeup of study
populations, illness diagnosis standards, and risk factor definitions.
• Only lately has the Burden of Obstructive Lung Diseases (BOLD) project given similar data from a
significant number of nations. There is little data on the prevalence of COPD in Eastern Europe.
Introduction
• Several recommendations on COPD diagnosis and management have been published. However, there are
no current recommendations for conducting research on COPD prevalence and severity in the general
community, covering population sampling, collecting, and quality control, as well as standardized methods
for providing information on possible risk factors for COPD.
• Smoking, occupational airborne exposure, and indoor and outdoor air pollution are all risk factors, as are
socioeconomic status, family history, diet, infections, and comorbidities.
• A standardized technique for conducting epidemiological COPD research might make it easier to compare
populations in Western and Eastern Europe.
• In respiratory research design, various epidemiological studies can be conducted to understand the
patterns, causes, and impact of respiratory diseases in populations. Here are some common types of
epidemiological studies in respiratory research:
Recommendations on COPD
diagnosis
• Cross-Sectional Studies
• Case-Control Studies
• Cohort Studies
• Longitudinal Studies
• Intervention Studies (Clinical Trials)
• Ecological Studies
• Occupational Studies
• Genetic Studies
• Surveillance Studies
• Meta-analyses and Systematic Reviews
• These epidemiological studies play a crucial role in advancing our understanding of respiratory diseases,
guiding public health interventions, and informing clinical practice.
• Previous COPD population studies utilized a range of operational diagnostic criteria, most of which were
based on lung function, respiratory symptoms, and clinical examination.
• In community research, any operational criteria should be valid, repeatable, and simple to use.
Obstructive abnormality is defined as a ratio of forced expiratory volume in 1 s (FEV1) to slow vital
capacity (SVC) less than the 5th percentile of the normal distribution in the American Thoracic Society
(ATS)/ERS report on interpretation methodologies for lung function tests.
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion of FEV1/forced vital capacity
(FVC) is 0.70, and the British Thoracic Society (BTS) standard of FEV1/vital capacity (VC) 70% and FEV1
80% of projected value deviate from this definition.
Operational diagnostic criteria
of COPD
• Lung function
Lung function measurements should follow
ATS/ERS recommendations, with COPD staging
based on airflow limitations. clinical epidemiology
and biostatistics guidelines by ATS/ERS and GOLD
present arbitrary categories and cut-off points.
• Biomarkers
A biomarker is a biological marker that may be
examined and assessed objectively as a sign of
normal biological processes, pathological
processes, pharmaceutical or pharmacological
reactions to a therapeutic intervention.
• Phenotypes of COPD
The term "phenotype" refers to the outward
physical manifestation of COPD patients,
everything that is visible in their structure, function,
or behaviour. This provides a framework for
documenting the unique features of COPD
patients.
• Respiratory symptoms
Data on respiratory symptoms is crucial for
understanding COPD phenotypes, as cough and
sputum production may dominate clinical pictures
in some patients, while dyspnoea may dominate in
others.
ABOUT PUBRICA
• Pubrica's team of researchers and authors create scientific and
medical research services that may serve as a valuable resource
for practitioners and authors.
• Our systematic review at Pubrica is more structured at each stage
of writing, and we ensure that the rigour is critically checked using
common methodological checklists such as PRISMA, CASP,
AMSTAR, and ARIF, among others, depending on the checklist
supplied.
• Our professionals understand the framework that begins with a
broad topic, an issue, and a backdrop and progresses to a small
topic to present the hypothesis.
+44 1618186353
UNITED KINGDOM
+91-9884350006
INDIA
EMAIL
sales@pubrica.com
Contact Us

More Related Content

Similar to Case-control studies epidemiology | Clinical epidemiology and biostatistics | Respiratory research

Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometri...
Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometri...Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometri...
Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometri...
DR. SUJOY MUKHERJEE
 
Gold - global initiative against COPD
Gold - global initiative against COPDGold - global initiative against COPD
Gold - global initiative against COPD
adithya2115
 
PS_Lung Disease AAI2016_2173-Final
PS_Lung Disease AAI2016_2173-FinalPS_Lung Disease AAI2016_2173-Final
PS_Lung Disease AAI2016_2173-Final
Paul Younge
 
EXACERBATION OF COPD _ 11
EXACERBATION OF COPD _ 11EXACERBATION OF COPD _ 11
EXACERBATION OF COPD _ 11
SoM
 
Proefschrift Annerika Slok
Proefschrift Annerika SlokProefschrift Annerika Slok
Proefschrift Annerika Slok
Annerika Slok
 
OUTCOME MEASURES AND PROGNOSTIC MARKERS FOR COPD _4
OUTCOME MEASURES  AND PROGNOSTIC MARKERS FOR COPD _4OUTCOME MEASURES  AND PROGNOSTIC MARKERS FOR COPD _4
OUTCOME MEASURES AND PROGNOSTIC MARKERS FOR COPD _4
SoM
 
2005.copd_reportcard(luc Lapointe)
2005.copd_reportcard(luc Lapointe)2005.copd_reportcard(luc Lapointe)
2005.copd_reportcard(luc Lapointe)
Luc Lapointe
 
CO- MORBIDITIES AND SYSTEMIC EFFECTS OF COPD
CO- MORBIDITIES AND SYSTEMIC EFFECTS OF COPDCO- MORBIDITIES AND SYSTEMIC EFFECTS OF COPD
CO- MORBIDITIES AND SYSTEMIC EFFECTS OF COPD
SoM
 

Similar to Case-control studies epidemiology | Clinical epidemiology and biostatistics | Respiratory research (20)

M mrc scale
M mrc scaleM mrc scale
M mrc scale
 
Obstructive Sleep Apnoea Working Group Meeting
Obstructive Sleep Apnoea Working Group MeetingObstructive Sleep Apnoea Working Group Meeting
Obstructive Sleep Apnoea Working Group Meeting
 
Bronchiectasis
BronchiectasisBronchiectasis
Bronchiectasis
 
COPD
COPDCOPD
COPD
 
Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometri...
Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometri...Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometri...
Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometri...
 
REG IPF/ILD Working Group Meeting 25/09/15
REG IPF/ILD Working Group Meeting 25/09/15REG IPF/ILD Working Group Meeting 25/09/15
REG IPF/ILD Working Group Meeting 25/09/15
 
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi DeleChronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
 
Gold - global initiative against COPD
Gold - global initiative against COPDGold - global initiative against COPD
Gold - global initiative against COPD
 
YUVA THANJAVUR COPD DAY.pptx
YUVA THANJAVUR COPD DAY.pptxYUVA THANJAVUR COPD DAY.pptx
YUVA THANJAVUR COPD DAY.pptx
 
Copd in never smokers
Copd in never smokersCopd in never smokers
Copd in never smokers
 
Prof. Todor (Ted) A. Popov - 6th Clinical Research Conference
Prof. Todor (Ted) A. Popov - 6th Clinical Research ConferenceProf. Todor (Ted) A. Popov - 6th Clinical Research Conference
Prof. Todor (Ted) A. Popov - 6th Clinical Research Conference
 
PS_Lung Disease AAI2016_2173-Final
PS_Lung Disease AAI2016_2173-FinalPS_Lung Disease AAI2016_2173-Final
PS_Lung Disease AAI2016_2173-Final
 
EXACERBATION OF COPD _ 11
EXACERBATION OF COPD _ 11EXACERBATION OF COPD _ 11
EXACERBATION OF COPD _ 11
 
Proefschrift Annerika Slok
Proefschrift Annerika SlokProefschrift Annerika Slok
Proefschrift Annerika Slok
 
Indian guidelines for COPD
Indian guidelines for COPDIndian guidelines for COPD
Indian guidelines for COPD
 
Mesa 1.2 borja garcía cosío
Mesa 1.2 borja garcía cosíoMesa 1.2 borja garcía cosío
Mesa 1.2 borja garcía cosío
 
OUTCOME MEASURES AND PROGNOSTIC MARKERS FOR COPD _4
OUTCOME MEASURES  AND PROGNOSTIC MARKERS FOR COPD _4OUTCOME MEASURES  AND PROGNOSTIC MARKERS FOR COPD _4
OUTCOME MEASURES AND PROGNOSTIC MARKERS FOR COPD _4
 
Breakout 1.2 Assessing competence in practice: Quality assured diagnostic spi...
Breakout 1.2 Assessing competence in practice: Quality assured diagnostic spi...Breakout 1.2 Assessing competence in practice: Quality assured diagnostic spi...
Breakout 1.2 Assessing competence in practice: Quality assured diagnostic spi...
 
2005.copd_reportcard(luc Lapointe)
2005.copd_reportcard(luc Lapointe)2005.copd_reportcard(luc Lapointe)
2005.copd_reportcard(luc Lapointe)
 
CO- MORBIDITIES AND SYSTEMIC EFFECTS OF COPD
CO- MORBIDITIES AND SYSTEMIC EFFECTS OF COPDCO- MORBIDITIES AND SYSTEMIC EFFECTS OF COPD
CO- MORBIDITIES AND SYSTEMIC EFFECTS OF COPD
 

More from Pubrica

More from Pubrica (20)

What are the differences in publishing diabetes epidemiological manuscripts.pdf
What are the differences in publishing diabetes epidemiological manuscripts.pdfWhat are the differences in publishing diabetes epidemiological manuscripts.pdf
What are the differences in publishing diabetes epidemiological manuscripts.pdf
 
Medical case series | Writing services the clinical case report for Scientif...
 Medical case series | Writing services the clinical case report for Scientif... Medical case series | Writing services the clinical case report for Scientif...
Medical case series | Writing services the clinical case report for Scientif...
 
Clinical Cohort Studies | Peer review process | Scientific publication
Clinical Cohort Studies | Peer review process | Scientific publicationClinical Cohort Studies | Peer review process | Scientific publication
Clinical Cohort Studies | Peer review process | Scientific publication
 
Research and Scientific Journal Publication support services | Research pape...
 Research and Scientific Journal Publication support services | Research pape... Research and Scientific Journal Publication support services | Research pape...
Research and Scientific Journal Publication support services | Research pape...
 
How Randomized Controlled Trials are Used in Meta-Analysis
How Randomized Controlled Trials are Used in Meta-Analysis How Randomized Controlled Trials are Used in Meta-Analysis
How Randomized Controlled Trials are Used in Meta-Analysis
 
Statistical analyses services | Pharmaceutical writing companies | Statistica...
Statistical analyses services | Pharmaceutical writing companies | Statistica...Statistical analyses services | Pharmaceutical writing companies | Statistica...
Statistical analyses services | Pharmaceutical writing companies | Statistica...
 
Systematic literature review services | Cardiovascular research | Bariatric s...
Systematic literature review services | Cardiovascular research | Bariatric s...Systematic literature review services | Cardiovascular research | Bariatric s...
Systematic literature review services | Cardiovascular research | Bariatric s...
 
Electronic health records | Data collection systems | Data collection and ana...
Electronic health records | Data collection systems | Data collection and ana...Electronic health records | Data collection systems | Data collection and ana...
Electronic health records | Data collection systems | Data collection and ana...
 
Assessing Evidence-Based Practice in Physical Therapy: A Multifaceted Mixed-M...
Assessing Evidence-Based Practice in Physical Therapy: A Multifaceted Mixed-M...Assessing Evidence-Based Practice in Physical Therapy: A Multifaceted Mixed-M...
Assessing Evidence-Based Practice in Physical Therapy: A Multifaceted Mixed-M...
 
A comprehensive study of clinical efficacy in cochlear implant surgery among ...
A comprehensive study of clinical efficacy in cochlear implant surgery among ...A comprehensive study of clinical efficacy in cochlear implant surgery among ...
A comprehensive study of clinical efficacy in cochlear implant surgery among ...
 
Cytotoxic | Primary research | Silver nanoparticles
Cytotoxic | Primary research | Silver nanoparticlesCytotoxic | Primary research | Silver nanoparticles
Cytotoxic | Primary research | Silver nanoparticles
 
Journal article | Original research article | Qualitative and quantitative re...
Journal article | Original research article | Qualitative and quantitative re...Journal article | Original research article | Qualitative and quantitative re...
Journal article | Original research article | Qualitative and quantitative re...
 
What are the suggestions given by peer reviewers in the introduction section ...
What are the suggestions given by peer reviewers in the introduction section ...What are the suggestions given by peer reviewers in the introduction section ...
What are the suggestions given by peer reviewers in the introduction section ...
 
Addressing to Reviewers’ Comments.pdf
Addressing to Reviewers’ Comments.pdfAddressing to Reviewers’ Comments.pdf
Addressing to Reviewers’ Comments.pdf
 
Manuscript review guidelines | Manuscript peer reviewer | Address Reviewer Co...
Manuscript review guidelines | Manuscript peer reviewer | Address Reviewer Co...Manuscript review guidelines | Manuscript peer reviewer | Address Reviewer Co...
Manuscript review guidelines | Manuscript peer reviewer | Address Reviewer Co...
 
Experimental research design | Descriptive quantitative research | Data colle...
Experimental research design | Descriptive quantitative research | Data colle...Experimental research design | Descriptive quantitative research | Data colle...
Experimental research design | Descriptive quantitative research | Data colle...
 
Data gathering | Primary data collection | Healthcare blockchain
Data gathering | Primary data collection | Healthcare blockchainData gathering | Primary data collection | Healthcare blockchain
Data gathering | Primary data collection | Healthcare blockchain
 
Narrative review | Systematic review | Data extraction
Narrative review | Systematic review | Data extractionNarrative review | Systematic review | Data extraction
Narrative review | Systematic review | Data extraction
 
Narrative review | Prisma systematic review | Medical writing
Narrative review | Prisma systematic review | Medical writingNarrative review | Prisma systematic review | Medical writing
Narrative review | Prisma systematic review | Medical writing
 
Meta analysis between Helicobacter Pylori infection and ABO blood groups
Meta analysis between Helicobacter Pylori infection and ABO blood groupsMeta analysis between Helicobacter Pylori infection and ABO blood groups
Meta analysis between Helicobacter Pylori infection and ABO blood groups
 

Recently uploaded

Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Peter Udo Diehl
 

Recently uploaded (20)

Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfIntroduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
 
WebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM PerformanceWebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM Performance
 
How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdf
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
 
IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
 
Speed Wins: From Kafka to APIs in Minutes
Speed Wins: From Kafka to APIs in MinutesSpeed Wins: From Kafka to APIs in Minutes
Speed Wins: From Kafka to APIs in Minutes
 
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
 
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
 
Demystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John StaveleyDemystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John Staveley
 
THE BEST IPTV in GERMANY for 2024: IPTVreel
THE BEST IPTV in  GERMANY for 2024: IPTVreelTHE BEST IPTV in  GERMANY for 2024: IPTVreel
THE BEST IPTV in GERMANY for 2024: IPTVreel
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
 
Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024
 
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptxUnpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
 
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdfSimplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
 
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone KomSalesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
 
Oauth 2.0 Introduction and Flows with MuleSoft
Oauth 2.0 Introduction and Flows with MuleSoftOauth 2.0 Introduction and Flows with MuleSoft
Oauth 2.0 Introduction and Flows with MuleSoft
 
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfLinux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
 
Intro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджераIntro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджера
 

Case-control studies epidemiology | Clinical epidemiology and biostatistics | Respiratory research

  • 1. What are the different epidemiological studies that can be conducted in respiratory research An Academic presentation by Dr. Nancy Agnes, Head, Technical Operations, Pubrica Group: www.pubrica.com Email: sales@pubrica.com
  • 2. • Chronic obstructive pulmonary disease (COPD) prevalence has been thoroughly investigated, particularly in Western Europe and North America. • Few of these data are directly comparable because of survey discrepancies in the mix of research populations, disease diagnosis standards, and risk factor definitions. • Few community studies have explored COPD phenotypes and incorporated methods of characterizing the illness other than spirometry. In brief
  • 3. • Chronic obstructive pulmonary disease (COPD) is now the fourth leading cause of mortality globally. The illness is anticipated to reach third place by 2020. • COPD prevalence has been thoroughly researched, particularly in Western Europe and North America. However, few of the data are directly comparable due to changes in the surveys' makeup of study populations, illness diagnosis standards, and risk factor definitions. • Only lately has the Burden of Obstructive Lung Diseases (BOLD) project given similar data from a significant number of nations. There is little data on the prevalence of COPD in Eastern Europe. Introduction
  • 4.
  • 5. • Several recommendations on COPD diagnosis and management have been published. However, there are no current recommendations for conducting research on COPD prevalence and severity in the general community, covering population sampling, collecting, and quality control, as well as standardized methods for providing information on possible risk factors for COPD. • Smoking, occupational airborne exposure, and indoor and outdoor air pollution are all risk factors, as are socioeconomic status, family history, diet, infections, and comorbidities. • A standardized technique for conducting epidemiological COPD research might make it easier to compare populations in Western and Eastern Europe. • In respiratory research design, various epidemiological studies can be conducted to understand the patterns, causes, and impact of respiratory diseases in populations. Here are some common types of epidemiological studies in respiratory research: Recommendations on COPD diagnosis
  • 6. • Cross-Sectional Studies • Case-Control Studies • Cohort Studies • Longitudinal Studies • Intervention Studies (Clinical Trials) • Ecological Studies • Occupational Studies • Genetic Studies • Surveillance Studies • Meta-analyses and Systematic Reviews • These epidemiological studies play a crucial role in advancing our understanding of respiratory diseases, guiding public health interventions, and informing clinical practice.
  • 7. • Previous COPD population studies utilized a range of operational diagnostic criteria, most of which were based on lung function, respiratory symptoms, and clinical examination. • In community research, any operational criteria should be valid, repeatable, and simple to use. Obstructive abnormality is defined as a ratio of forced expiratory volume in 1 s (FEV1) to slow vital capacity (SVC) less than the 5th percentile of the normal distribution in the American Thoracic Society (ATS)/ERS report on interpretation methodologies for lung function tests. • The Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion of FEV1/forced vital capacity (FVC) is 0.70, and the British Thoracic Society (BTS) standard of FEV1/vital capacity (VC) 70% and FEV1 80% of projected value deviate from this definition. Operational diagnostic criteria of COPD
  • 8. • Lung function Lung function measurements should follow ATS/ERS recommendations, with COPD staging based on airflow limitations. clinical epidemiology and biostatistics guidelines by ATS/ERS and GOLD present arbitrary categories and cut-off points. • Biomarkers A biomarker is a biological marker that may be examined and assessed objectively as a sign of normal biological processes, pathological processes, pharmaceutical or pharmacological reactions to a therapeutic intervention. • Phenotypes of COPD The term "phenotype" refers to the outward physical manifestation of COPD patients, everything that is visible in their structure, function, or behaviour. This provides a framework for documenting the unique features of COPD patients. • Respiratory symptoms Data on respiratory symptoms is crucial for understanding COPD phenotypes, as cough and sputum production may dominate clinical pictures in some patients, while dyspnoea may dominate in others.
  • 9. ABOUT PUBRICA • Pubrica's team of researchers and authors create scientific and medical research services that may serve as a valuable resource for practitioners and authors. • Our systematic review at Pubrica is more structured at each stage of writing, and we ensure that the rigour is critically checked using common methodological checklists such as PRISMA, CASP, AMSTAR, and ARIF, among others, depending on the checklist supplied. • Our professionals understand the framework that begins with a broad topic, an issue, and a backdrop and progresses to a small topic to present the hypothesis.